InvestorTalk Alert: Brent Willis from Voyageur Pharmaceuticals Ltd. to host on Wednesday, May 29, 2024


InvestorNews is pleased to announce an upcoming InvestorTalk scheduled for tomorrow, Wednesday, May 29th, at 9 AM EST, featuring Brent Willis, the President, CEO, and Director of Voyageur Pharmaceuticals Ltd. (TSXV: VM). To participate in this engaging discussion, please click here

Currently, Voyageur Pharmaceuticals holds 138,881,576 shares outstanding and has a market capitalization of CAD$6,249,671.

In preparation for tomorrow’s InvestorTalk, here are the three most recent news releases from Voyageur Pharmaceuticals for your review:

  • May 28, 2024 — Voyageur Pharmaceuticals Ltd Secures USD $1.9 Million Sales Contract for SmoothX 2% Barium Contrast — click here
  • April 3, 2024 — Voyageur Pharmaceuticals Ltd Grants Deferred Share Units Compensation to Independent Directors — click here
  • March 26, 2024 — Voyageur Pharmaceuticals Files Audited Annual Financial Statements and Grants Stock Options — click here

5-Data Points from Voyageur’s most recent news release on May 28, 2024, titled, Voyageur Pharmaceuticals Ltd Secures USD $1.9 Million Sales Contract for SmoothX 2% Barium Contrast:

  • Sales Contract Value: Voyageur Pharmaceuticals has secured a sales contract valued at USD $1.9 million (CAD $2.6 million) for the first three years of commercialization of their SmoothX 2% barium contrast medium.
  • International Expansion: This contract marks the company’s first international distribution agreement, targeting the radiology product market in Latin America and involving marketing and sales rights in two countries.
  • Expansion into U.S. Market: Voyageur plans to expand into the U.S. market, leveraging regulatory approvals and successes in other countries to introduce its innovative imaging products.
  • Future Product Line: Voyageur has four additional barium sulfate contrast medium products at late stages of development, which include high-density and low-density solutions for various gastrointestinal radiographic examinations.
  • Corporate Strategy and Commitment: Voyageur is planning to expand into the U.S. market and aims to become a vertically integrated, carbon-neutral company in the radiology contrast media drug market, emphasizing sustainability and cost efficiency.

(05.28.2024 at 12:00 PM EST, Source)

For more information on Voyageur Pharmaceuticals Ltd., click here.

For more information on the InvestorTalk pre-market series, go to

Disclaimer: The author of this Investor.News post, which is published by InvestorNews Inc., may or may not be a shareholder of any of the companies mentioned in this column. No company mentioned has sponsored or paid for this content on Investor.News, and InvestorNews Inc. does not accept opt-in payments from advertisers. While InvestorNews Inc. provides digital media services like video interviews and podcasts to advertisers, not all are paid promotions. Any sponsored video interview will be clearly marked in the summary. The author of this piece is not a licensed investment advisor and makes no recommendations to buy, sell, or hold any securities. If the author holds an investment advisor license, this will be stated in their biography. Conduct your own due diligence by reviewing public documents of any company. For our full legal notices and disclaimers, click here click here.

Leave a Reply

Your email address will not be published. Required fields are marked *